|Bid||170.06 x 800|
|Ask||178.49 x 1000|
|Day's Range||176.51 - 178.13|
|52 Week Range||108.85 - 209.00|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||41.40|
|Earnings Date||Oct 22, 2020 - Oct 26, 2020|
|Forward Dividend & Yield||1.56 (0.88%)|
|Ex-Dividend Date||Aug 19, 2020|
|1y Target Est||184.00|
ResMed Inc (RMD)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on June 30, 2020. Continue reading...
VIDA Diagnostics, Inc. ("VIDA"), the leader in lung and respiratory intelligence, announced today that it is has appointed Karen Drexler to its board of directors, further expanding the company's leadership strength in digital health technology. Drexler's appointment comes at a critical time in healthcare, as the world continues to address the potential long-term lung health implications of the COVID-19 pandemic. VIDA, with its suite of AI-powered lung intelligence solutions and analytics, is uniquely positioned to modernize lung and respiratory care for patients with or at risk of a variety of complex lung diseases.
ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.